Esta Claro que J&J en esta ocasión y con el nuevo Contrato alcanzado en 2011 Si Apuesta por Yondelis en Sarcoma para EEUU y resto de Paises en los que aún no esta Aprobado .
*********************************
Brief title A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma .
Official title A Randomized Controlled Study of YONDELIS (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma .
Recruitment Information
Status Recruiting
Start date 2011-06
Last follow-up date 2014-07 (Anticipated)
Primary completion date 2014-04 (Anticipated)
Administrative Data
Organization name Janssen Research & Development, LLC
Organization study ID CR018004
Secondary ID ET743SAR3007 (Janssen Research & Development, LLC)
Sponsor Janssen Research & Development, LLC
Collaborator Pharma Mar, S.A.U.
Health Authority United States: Food and Drug Administration
Health Authority Australia: Department of Health and Ageing Therapeutic Goods Administration
Health Authority New Zealand: Health Research Council
Health Authority South Africa: Medicines Control Council
Health Authority Brazil: Ministry of Health
